A single-center, open-label, off-label use investigator-initiated clinical study with safety
run-in to explore the clinical activity and safety of Anti-CD38 Antibody in adult ES patients
who have not responded adequately or relapsed after first-line treatment and at least one
second-line therapy including immunosuppressive agents, Anti-CD20 Antibody and/or TPO-RA, or
those in whom no other second-line treatment options are suitable.
Phase:
Phase 2
Details
Lead Sponsor:
Institute of Hematology & Blood Diseases Hospital, China